625 related articles for article (PubMed ID: 26218843)
1. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF;
PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843
[TBL] [Abstract][Full Text] [Related]
2. Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C.
Piedoux S; Monnet E; Piroth L; Montange D; Royer B; Thevenot T; Kantelip JP; Di Martino V; Muret P;
Antivir Ther; 2011; 16(8):1317-26. PubMed ID: 22155913
[TBL] [Abstract][Full Text] [Related]
3. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P
Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927
[TBL] [Abstract][Full Text] [Related]
5. Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
Bruno G; Fasano M; Saracino A; Volpe A; Bartolomeo N; Ladisa N; Maggi P; Monno L; Angarano G
New Microbiol; 2015 Jan; 38(1):21-7. PubMed ID: 25742144
[TBL] [Abstract][Full Text] [Related]
6. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
[TBL] [Abstract][Full Text] [Related]
7. Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome.
Boesecke C; Ingiliz P; Reiberger T; Stellbrink HJ; Bhagani S; Page E; Mauss S; Lutz T; Voigt E; Guiguet M; Valantin MA; Baumgarten A; Nelson M; Vogel M; Rockstroh JK;
Infection; 2016 Feb; 44(1):93-101. PubMed ID: 26481253
[TBL] [Abstract][Full Text] [Related]
8. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
[TBL] [Abstract][Full Text] [Related]
9. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
Martín-Carbonero L; Puoti M; García-Samaniego J; De Luca A; Losada E; Quinzan G; Bruno R; Mariño A; González M; Núñez M; Soriano V
J Viral Hepat; 2008 Oct; 15(10):710-5. PubMed ID: 18637070
[TBL] [Abstract][Full Text] [Related]
10. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
[TBL] [Abstract][Full Text] [Related]
11. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
Mira JA; Valera-Bestard B; Arizcorreta-Yarza A; González-Serrano M; Torre-Cisneros J; Santos I; Vergara S; Gutiérrez-Valencia A; Girón-González JA; Macías J; López-Cortés LF; Pineda JA
Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561
[TBL] [Abstract][Full Text] [Related]
12. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
[TBL] [Abstract][Full Text] [Related]
13. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA;
Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784
[TBL] [Abstract][Full Text] [Related]
14. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
[TBL] [Abstract][Full Text] [Related]
15. The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study.
Kurniawan J; Gani RA; Djauzi S; Ibrahim F; Harimurti K; Nafrialdi N; Imannuel S
Acta Med Indones; 2019 Apr; 51(2):128-136. PubMed ID: 31383827
[TBL] [Abstract][Full Text] [Related]
16. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
17. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF
J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
[TBL] [Abstract][Full Text] [Related]
18. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B;
Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715
[TBL] [Abstract][Full Text] [Related]
19. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
20. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
